ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Tau burden is best captured by magnitude and extent: Tau-MaX as a measure of global tau.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Group-level versus individualized approaches for capturing tau PET changes and clinical progression in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Article
- Vulnerability of anterior medial temporal lobe subregions to early tau-related neurodegeneration in Alzheimer's disease: Converging evidence from tau-PET and plasma p-tau217.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration.Acta neuropathologica · 2026Article
- Uncovering distinct spatiotemporal trajectories of T-N mismatch subtypes with likely co-pathology in Alzheimer's disease using event-based modeling.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Medial temporal lobe Tau-Neurodegeneration mismatch from structural imaging and plasma biomarkers.Brain : a journal of neurology · 2026Article
- Florzolotau (18F) retention is linked to neuropsychological performance in tauopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Brain network dynamics determine tau presence while regional vulnerability governs tau load in Alzheimer's disease.Research square · 2026Article
- Enrichment of patients with concomitant limbic-predominant age-related TDP-43 encephalopathy (LATE) on the Alzheimer's disease continuum using hippocampal volume.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Primary age-related tauopathy.Acta neuropathologica · 2025Review
- Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease using PET and Plasma Biomarkers.medRxiv : the preprint server for health sciences · 2025Article
- Tau-Clinical Mismatch Identifies Individuals with Co-Pathology and Predicts Clinical Trajectory.medRxiv : the preprint server for health sciences · 2025Article
- Tau burden is best captured by magnitude and extent: Tau-MaX as a measure of global tau.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Tau, atrophy, and domain-specific cognitive impairment in typical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Fully individualized models for cross-sectional and longitudinal network-based tau spread.Imaging neuroscience (Cambridge, Mass.) · 2025Article
Corrections and comments
- Update of
Authors and funding
13 authors.
Funding
Abstract
introductionTau burden consists of both spatial spread and local accumulation, but no study has combined these measures into a single metric to capture overall global tau burden. Here we investigate a new measure combining magnitude and extent-Tau-MaX-as a marker of Alzheimer's disease (AD) severity.
methodsA total of 1077
resultsTau-MaX dynamically captured an early shift in spatial spreading to later tau accumulation across the disease spectrum. Tau-MaX had robust associations with plasma biomarkers and cross-sectional and longitudinal cognition. Global Tau-MaX was equivalent to or superior to magnitude or extent measures alone. DISCUSSION: Tau-MaX provides a region-agnostic measure of global tau burden that can be used to track disease progression across the AD continuum. HIGHLIGHTS: We measured tau extent, magnitude, and a new combination of these metrics, Tau-MaX. Extent increases early in disease, while magnitude increases in later disease stages. Tau-MaX captures this shift and is closely associated with phosphorylated tau217 and cognition. Global Tau-MaX performed similarly to or better than meta-region of interest tau magnitude or extent. Tau-MaX provides a region-agnostic measure of tau burden to track progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.